The prognostic value of positive T wave in lead aVR: A novel marker of adverse cardiac outcomes in peripartum cardiomyopathy.


Journal

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
ISSN: 1542-474X
Titre abrégé: Ann Noninvasive Electrocardiol
Pays: United States
ID NLM: 9607443

Informations de publication

Date de publication:
05 2019
Historique:
received: 24 09 2018
revised: 28 10 2018
accepted: 03 11 2018
pubmed: 18 1 2019
medline: 20 5 2020
entrez: 18 1 2019
Statut: ppublish

Résumé

Peripartum cardiomyopathy (PPCM) is an uncommon complication of pregnancy. Clinical courses of PPCM are markedly heterogeneous. Positive T waves in lead aVR (TaVR) are shown to be associated with adverse cardiac events in several cardiovascular diseases. We aimed to investigate the prevalence and prognostic role of positive TaVR in patients with PPCM. A total of 82 patients (mean age 29.1 ± 6.3 years) with the diagnosis of PPCM were enrolled. Presentation electrocardiogram (ECG) was investigated for presence of a positive TaVR. The median follow-up duration was 67.0 months. The primary endpoint was defined as composite cardiac events, including cardiac death, arrhythmic events, or persistent left ventricular systolic dysfunction. Patients with positive T wave in lead aVR showed higher rates for persistent left ventricular systolic dysfunction, arrhythmic events, and cardiac death compared to patients without it. In multivariate logistic regression analysis, after adjusting for other confounding factors, the presence of positive TaVR was found to be as an independent and strong predictor of primary composite endpoint (odds ratio 6.21, 95% CI 1.45-26.51; p = 0.014). In Kaplan-Meier survival analysis, both primary and secondary endpoints occurred more frequently in the positive TaVR group. Using the cut-off level of 0.25 mV, T-wave amplitude in lead aVR predicted primary endpoint with a sensitivity of 100% and specificity of 100%. Positive T wave in lead aVR, as a simple and feasible electrocardiographic marker, seems to be a novel predictor of adverse cardiovascular outcomes in patients with PPCM.

Sections du résumé

BACKGROUND
Peripartum cardiomyopathy (PPCM) is an uncommon complication of pregnancy. Clinical courses of PPCM are markedly heterogeneous. Positive T waves in lead aVR (TaVR) are shown to be associated with adverse cardiac events in several cardiovascular diseases. We aimed to investigate the prevalence and prognostic role of positive TaVR in patients with PPCM.
METHODS
A total of 82 patients (mean age 29.1 ± 6.3 years) with the diagnosis of PPCM were enrolled. Presentation electrocardiogram (ECG) was investigated for presence of a positive TaVR. The median follow-up duration was 67.0 months. The primary endpoint was defined as composite cardiac events, including cardiac death, arrhythmic events, or persistent left ventricular systolic dysfunction.
RESULTS
Patients with positive T wave in lead aVR showed higher rates for persistent left ventricular systolic dysfunction, arrhythmic events, and cardiac death compared to patients without it. In multivariate logistic regression analysis, after adjusting for other confounding factors, the presence of positive TaVR was found to be as an independent and strong predictor of primary composite endpoint (odds ratio 6.21, 95% CI 1.45-26.51; p = 0.014). In Kaplan-Meier survival analysis, both primary and secondary endpoints occurred more frequently in the positive TaVR group. Using the cut-off level of 0.25 mV, T-wave amplitude in lead aVR predicted primary endpoint with a sensitivity of 100% and specificity of 100%.
CONCLUSION
Positive T wave in lead aVR, as a simple and feasible electrocardiographic marker, seems to be a novel predictor of adverse cardiovascular outcomes in patients with PPCM.

Identifiants

pubmed: 30653267
doi: 10.1111/anec.12631
pmc: PMC6931550
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12631

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Intern Med. 2012;51(5):461-4
pubmed: 22382559
Heart Vessels. 2012 Nov;27(6):548-52
pubmed: 21969217
Eur J Heart Fail. 2008 Sep;10(9):861-8
pubmed: 18768352
Curr Cardiol Rev. 2014 Nov;10(4):317-26
pubmed: 24646160
Am J Cardiol. 2011 Dec 15;108(12):1735-40
pubmed: 21906704
Ther Apher Dial. 2017 Jun;21(3):287-294
pubmed: 28296251
Ann Noninvasive Electrocardiol. 2011 Jul;16(3):250-7
pubmed: 21762252
Ann Noninvasive Electrocardiol. 2017 Nov;22(6):
pubmed: 28440568
Am Heart J. 2006 Sep;152(3):509-13
pubmed: 16923422
J Cardiol. 2011 Mar;57(2):160-4
pubmed: 21316193
Ann Noninvasive Electrocardiol. 2016 Jan;21(1):91-7
pubmed: 25884447
Ann Noninvasive Electrocardiol. 2019 May;24(3):e12631
pubmed: 30653267
Am J Cardiol. 2013 Sep 15;112(6):805-10
pubmed: 23764245
Mayo Clin Proc. 2005 Dec;80(12):1602-6
pubmed: 16342653
Int J Cardiol. 2011 Nov 17;153(1):1-3
pubmed: 21945711
Ann Noninvasive Electrocardiol. 2008 Apr;13(2):113-9
pubmed: 18426436
Ann Noninvasive Electrocardiol. 2013 Jan;18(1):51-7
pubmed: 23347026
Exp Clin Cardiol. 2010 Summer;15(2):e36-44
pubmed: 20631863
Expert Rev Cardiovasc Ther. 2011 Sep;9(9):1155-60
pubmed: 21932958
Cardiovasc J Afr. 2012 Jul;23(6):322-9
pubmed: 22337203
Int J Cardiol. 2013 Mar 20;164(1):33-8
pubmed: 22192299
Ann Noninvasive Electrocardiol. 2018 Sep;23(5):e12554
pubmed: 29676045
Obstet Gynecol. 2005 Jun;105(6):1303-8
pubmed: 15932821
Circulation. 2009 Mar 17;119(10):e241-50
pubmed: 19228821
J Am Coll Cardiol. 2015 Aug 25;66(8):905-14
pubmed: 26293760
Eur J Heart Fail. 2010 Aug;12(8):767-78
pubmed: 20675664
J Card Fail. 2009 Oct;15(8):645-50
pubmed: 19786252
J Am Coll Cardiol. 2009 Mar 17;53(11):982-91
pubmed: 19281931

Auteurs

Firdevs Aysenur Ekizler (FA)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Serkan Cay (S)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Habibe Kafes (H)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Ozcan Ozeke (O)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Firat Ozcan (F)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Serkan Topaloglu (S)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Ahmet Temizhan (A)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Dursun Aras (D)

Department of Cardiology, Turkiye Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH